中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 9
Sep.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(9): 2237-2243

Role of fecal microbiota transplantation in chronic liver diseases

DOI: 10.3969/j.issn.1001-5256.2023.09.031

  • Department of Infectious Diseases，The Second Affiliated Hospital of Air Force Medical University，Xi’an 710038，China

Research funding:

Shaanxi Province Key Research and Development Plan (2022SF－186)

More Information
  • Corresponding author: LIAN Jianqi， lianjq@fmmu.edu.cn （ORCID： 0000－0002－5549－7590）
  • Received Date: 2022-11-21
  • Accepted Date: 2023-01-02
  • Published Date: 2023-09-19
    Abstract
  • Gut microbiota dysbiosis is closely associated with the development， progression， and prognosis of chronic liver diseases， while chronic liver diseases can aggravate gut microbiota dysbiosis， and the two interact with and influence each other. Through transplantation of fecal flora from healthy donors， fecal microbiota transplantation （FMT） directly reconstructs the intestinal flora of patients and maintains homeostasis， thereby achieving targeted therapeutic outcomes. In recent years， many basic research studies and clinical trials have proved FMT as a core therapeutic strategy for reconstructing intestinal flora and an important breakthrough point in treatment regimens for liver diseases. This article reviews the basic research， clinical studies， and future prospect of FMT in chronic liver diseases.

     

    • FullText(HTML)
  • loading
    • References(57)
  • [1]
    LAGIER JC, KHELAIFIA S, ALOU MT, et al. Culture of previously uncultured members of the human gut microbiota by culturomics[J]. Nat Microbiol, 2016, 1: 16203. DOI: 10.1038/nmicrobiol.2016.203.
    [2]
    ALBILLOS A, DE GOTTARDI A, RESCIGNO M. The gut－liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72( 3): 558－ 577. DOI: 10.1016/j.jhep.2019.10.003.
    [3]
    ZHANG FM, CUI BT, HE XX, et al. Microbiota transplantation: Concept, methodology and strategy for its modernization[J]. Protein Cell, 2018, 9( 5): 462－ 473. DOI: 10.1007/s13238－018－0541－8.
    [4]
    OOIJEVAAR RE, TERVEER EM, VERSPAGET HW, et al. Clinical application and potential of fecal microbiota transplantation[J]. Annu Rev Med, 2019, 70: 335－ 351. DOI: 10.1146/annurev－med－111717－122956.
    [5]
    CAMMAROTA G, IANIRO G, TILG H, et al. European consensus conference on faecal microbiota transplantation in clinical practice[J]. Gut, 2017, 66( 4): 569－ 580. DOI: 10.1136/gutjnl－2016－313017.
    [6]
    WANG Y, ZHANG S, BORODY TJ, et al. Encyclopedia of fecal microbiota transplantation: A review of effectiveness in the treatment of 85 diseases[J]. Chin Med J, 2022, 135( 16): 1927－ 1939. DOI: 10.1097/CM9.0000000000002339.
    [7]
    ARON－WISNEWSKY J, VIGLIOTTI C, WITJES J, et al. Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders[J]. Nat Rev Gastroenterol Hepatol, 2020, 17( 5): 279－ 297. DOI: 10.1038/s41575－020－0269－9.
    [8]
    DE MUNCK TJI, XU P, VERWIJS HJA, et al. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta－analysis[J]. Liver Int, 2020, 40( 12): 2906－ 2916. DOI: 10.1111/liv.14696.
    [9]
    ZHANG J. Progress in the relationship between gut microbiota and children non－alcoholic fatty liver disease[J]. Int J Pediatr, 2020, 47( 8): 522－ 527. DOI: 10.3760/cma.j.issn.1673－4408.2020.08.002.

    张晶. 肠道微生物与儿童非酒精性脂肪性肝病关系的研究进展[J]. 国际儿科学杂志, 2020, 47( 8): 522－ 527. DOI: 10.3760/cma.j.issn.1673－4408.2020.08.002.
    [10]
    LONG XX, LIU D, LI HT, et al. Research progress of intestinal flora in nonalcoholic fatty liver disease[J]. Shanghai Med J, 2021, 44( 11): 867－ 872. DOI: 10.19842/j.cnki.issn.0253－9934.2021.11.017.

    龙晓雪, 刘丹, 李华婷, 等. 肠道菌群在非酒精性脂肪性肝病中的研究进展[J]. 上海医学, 2021, 44( 11): 867－ 872. DOI: 10.19842/j.cnki.issn.0253－9934.2021.11.017.
    [11]
    TAN XY, LIU Y, LONG JG, et al. Trimethylamine N－oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease[J]. Mol Nutr Food Res, 2019, 63( 17): e1900257. DOI: 10.1002/mnfr.201900257.
    [12]
    ABENAVOLI L, MAURIZI V, RINNINELLA E, et al. Fecal microbiota transplantation in NAFLD treatment[J]. Medicina, 2022, 58( 11): 1559. DOI: 10.3390/medicina58111559.
    [13]
    LIANG FF, LU XJ, DENG ZL, et al. Effect of washed microbiota transplantation on patients with dyslipidemia in South China[J]. Front Endocrinol(Lausanne), 2022, 13: 827107. DOI: 10.3389/fendo.2022.827107. eCollection 2022.
    [14]
    YE Y, ZHENG L, ZHENG ED, et al. Changes of intestinal flora in patients with nonalcoholic fatty liver disease and therapeutic effect of fecal bacteria transplantation[J]. Chin J Integr Tradit West Med Dig, 2019, 27( 10): 758－ 763. DOI: 10.3969/j.issn.1671－038X.2019.10.09.

    叶毅, 郑亮, 郑恩典, 等. 非酒精性脂肪性肝病的肠道菌群变化及粪菌移植治疗作用研究[J]. 中国中西医结合消化杂志, 2019, 27( 10): 758－ 763. DOI: 10.3969/j.issn.1671－038X.2019.10.09.
    [15]
    BAJAJ JS. Alcohol, liver disease and the gut microbiota[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 4): 235－ 246. DOI: 10.1038/s41575－018－0099－1.
    [16]
    BAJAJ JS, HEUMAN DM, HYLEMON PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications[J]. J Hepatol, 2014, 60( 5): 940－ 947. DOI: 10.1016/j.jhep.2013.12.019.
    [17]
    LECLERCQ S, MATAMOROS S, CANI PD, et al. Intestinal permeability, gut－bacterial dysbiosis, and behavioral markers of alcohol－dependence severity[J]. Proc Natl Acad Sci U S A, 2014, 111( 42): E4485－E4493. DOI: 10.1073/pnas.1415174111.
    [18]
    YAN AW, FOUTS DE, BRANDL J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease[J]. Hepatology, 2011, 53( 1): 96－ 105. DOI: 10.1002/hep.24018.
    [19]
    PHILIPS CA, PANDE A, SHASTHRY SM, et al. Healthy donor fecal microbiota transplantation in steroid－ineligible severe alcoholic hepatitis: A pilot study[J]. Clin Gastroenterol Hepatol, 2017, 15( 4): 600－ 602. DOI: 10.1016/j.cgh.2016.10.029.
    [20]
    PHILIPS CA, PHADKE N, GANESAN K, et al. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis[J]. Indian J Gastroenterol, 2018, 37( 3): 215－ 225. DOI: 10.1007/s12664－018－0859－4.
    [21]
    WEN H, SHI YL. Correlation between liver function and intestinal flora in patients with hepatitis B virus infected liver cirrhosis[J]. Henan Med Res, 2022, 31( 9): 1651－ 1654.

    闻慧, 史玉领. 乙型肝炎病毒感染肝硬化患者肝功能与肠道菌群的相关性[J]. 河南医学研究, 2022, 31( 9): 1651－ 1654.
    [22]
    XING LK, DENG YD, YAO LQ, et al. Changes of intestinal flora in patients with hepatitis B liver cirrhosis[J]. J Pract Hepatol, 2020, 23( 2): 256－ 259. DOI: 10.3969/j.issn.1672－5069.2020.02.027.

    邢乐康, 邓永东, 姚立琼, 等. 乙型肝炎肝硬化患者肠道菌群变化研究[J]. 实用肝脏病杂志, 2020, 23( 2): 256－ 259. DOI: 10.3969/j.issn.1672－5069.2020.02.027.
    [23]
    LU HF, WU ZW, XU W, et al. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection[J]. Microb Ecol, 2011, 61( 3): 693－ 703. DOI: 10.1007/s00248－010－9801－8.
    [24]
    LI YG, YU ZJ, LI A, et al. Gut microbiota alteration and modulation in hepatitis B virus－related fibrosis and complications: Molecular mechanisms and therapeutic inventions[J]. World J Gastroenterol, 2022, 28( 28): 3555－ 3572. DOI: 10.3748/wjg.v28.i28.3555.
    [25]
    CHOU HH, CHIEN WH, WU LL, et al. Age－related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota[J]. Proc Natl Acad Sci U S A, 2015, 112( 7): 2175－ 2180. DOI: 10.1073/pnas.1424775112.
    [26]
    WANG JZ, ZHOU X, LI XR, et al. Fecal microbiota transplantation alters the outcome of hepatitis B virus infection in mice[J]. Front Cell Infect Microbiol, 2022, 12: 844132. DOI: 10.3389/fcimb.2022.844132.
    [27]
    REN YD, YE ZS, YANG LZ, et al. Fecal microbiota transplantation induces hepatitis B virus e－antigen(HBeAg) clearance in patients with positive HBeAg after long－term antiviral therapy[J]. Hepatology, 2017, 65( 5): 1765－ 1768. DOI: 10.1002/hep.29008.
    [28]
    MADSEN M, KIMER N, BENDTSEN F, et al. Fecal microbiota transplantation in hepatic encephalopathy: A systematic review[J]. Scand J Gastroenterol, 2021, 56( 5): 560－ 569. DOI: 10.1080/00365521.2021.1899277.
    [29]
    AHMAD J, KUMAR M, SARIN SK, et al. PS－163－Faecal microbiota transplantation with tenofovir is superior to tenofovir alone in improving clinical outcomes in acute－on－chronic liver failure due to hepatitis B: An open label randomized controlled trial(NCT02689245)[J]. J Hepatol, 2019, 70( 1): e102. DOI: 10.1016/S0618－8278(19)30181－1.
    [30]
    SARANGI AN, GOEL A, SINGH A, et al. Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration[J]. BMC Gastroenterol, 2017, 17( 1): 1－ 12. DOI: 10.1186/s12876－017－0683－9.
    [31]
    ARAB JP, MARTIN－MATEOS RM, SHAH VH. Gut－liver axis, cirrhosis and portal hypertension: The chicken and the egg[J]. Hepatol Int, 2018, 12( Suppl 1): 24－ 33. DOI: 10.1007/s12072－017－9798－x.
    [32]
    WANG WW, ZHANG Y, HUANG XB, et al. Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride－induced acute hepatic dysfunction[J]. World J Gastroenterol, 2017, 23( 38): 6983－ 6994. DOI: 10.3748/wjg.v23.i38.6983.
    [33]
    CHENG YW, ALHAFFAR D, SAHA S, et al. Fecal microbiota transplantation is safe and effective in patients with Clostridioidesdifficile infection and cirrhosis[J]. Clin Gastroenterol Hepatol, 2021, 19( 8): 1627－ 1634. DOI: 10.1016/j.cgh.2020.06.051.
    [34]
    DHIMAN RK, ROY A, PREMKUMAR M, et al. Single session fecal microbiota transplantation in decompensated cirrhosis: an initial experience of clinical endpoints[C]// The Liver Meeting Digital Experience™. AASLD, 2020.
    [35]
    WOODHOUSE C, EDWARDS L, MULLISH BH, et al. Results of the PROFIT trial, a PROspective randomised placebo－controlled feasibility trial of faecal mIcrobiota transplantation in advanced cirrhosis[J]. J Hepatol, 2020, 73: S77－S 78. DOI: 10.1016/S0168－8278(20)30687－5.
    [36]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38－ 44. DOI: 10.3969/j.issn.1001－5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38－ 44. DOI: 10.3969/j.issn.1001－5256.2019.01.007.
    [37]
    WANG FC, LI ZY, ZHANG WJ, et al. The significance of gut microbiota in acute－on－chronic liver failure[J]. J Clin Hepatol, 2022, 38( 7): 1667－ 1670. DOI: 10.3969/j.issn.1001－5256.2022.07.040.

    王富春, 李子怡, 张万洁, 等. 肠道菌群在慢加急性肝衰竭中的意义[J]. 临床肝胆病杂志, 2022, 38( 7): 1667－ 1670. DOI: 10.3969/j.issn.1001－5256.2022.07.040.
    [38]
    CHEN MX, WANG SY. Role of intestinal dysbacteriosis in the pathogenesis of acute－on－chronic hepatitis B liver failure[J]. J Clin Hepatol, 2019, 35( 3): 665－ 668. DOI: 10.3969/j.issn.1001－5256.2019.03.048.

    陈木兴, 王少扬. 肠道菌群失调在乙型肝炎相关慢加急性肝衰竭发病机制中的作用[J]. 临床肝胆病杂志, 2019, 35( 3): 665－ 668. DOI: 10.3969/j.issn.1001－5256.2019.03.048.
    [39]
    LIAO W, TANG Y, FAN WH, et al. Analysis of gut microbiota imbalance and its influencing factors in patients with chronic acute liver failure[J]. Trauma and Crit Medicine, 2021, 9( 5): 394－ 396. DOI: 10.16048/j.issn.2095－5561.2021.05.17.

    廖威, 唐艳, 范文瀚, 等. 慢加急性肝衰竭患者肠道菌群失调情况及影响因素分析[J]. 创伤与急危重病医学, 2021, 9( 5): 394－ 396. DOI: 10.16048/j.issn.2095－5561.2021.05.17.
    [40]
    GAO A, XU YJ, LU SW, et al. Effect of fecal microbiota transplantation on intestinal flora in mice with acute－on－chronic liver failure[J]. J Clin Hepatol, 2021, 37( 6): 1379－ 1385. DOI: 10.3969/j.issn.1001－5256.2021.06.031.

    高安, 徐玉静, 陆圣威, 等. 粪菌移植对慢加急性肝衰竭小鼠模型肠道菌群的影响[J]. 临床肝胆病杂志, 2021, 37( 6): 1379－ 1385. DOI: 10.3969/j.issn.1001－5256.2021.06.031.
    [41]
    LIU YM, FAN LD, CHENG Z, et al. Fecal transplantation alleviates acute liver injury in mice through regulating Treg/Th17 cytokines balance[J]. Sci Rep, 2021, 11( 1): 1611. DOI: 10.1038/s41598－021－81263－y.
    [42]
    SHARMA A, ROY A, PREMKUMAR M, et al. Fecal microbiota transplantation in alcohol－associated acute－on－chronic liver failure: An open－label clinical trial[J]. Hepatol Int, 2022, 16( 2): 433－ 446. DOI: 10.1007/s12072－022－10312－z.
    [43]
    LEI ZL, HUANG Y. Advances in research on intestinal flora imbalance in the development and prevention of liver cancer[J]. Anti Tumor Pharm, 2020, 10( 1): 16－ 20. DOI: 10.3969/j.issn.2095－1264.2020.01.04.

    雷中利, 黄燕. 肠道菌群失调在肝癌发生、‍发展和预防、‍治疗中的研究进展[J]. 肿瘤药学, 2020, 10( 1): 16－ 20. DOI: 10.3969/j.issn.2095－1264.2020.01.04.
    [44]
    DENG HD, FAN XL. The role of intestinal microbiota in tumor occurrence, development and immunotherapy: A review[J]. Chin J Biotechnol, 2022, 38( 6): 2105－ 2119. DOI: 10.13345/j.cjb.210711.

    邓寒丹, 范兴丽. 肠道菌群在肿瘤发生发展及免疫治疗中作用的研究进展[J]. 生物工程学报, 2022, 38( 6): 2105－ 2119. DOI: 10.13345/j.cjb.210711.
    [45]
    ZHENG W, ZHANG YH, ZHAO Y. Role of intestinal microflora in the pathogenesis of hepatocellular carcinoma[J]. J Clin Hepatol, 2019, 35( 7): 1613－ 1615. DOI: 10.3969/j.issn.1001－5256.2019.07.041.

    郑微, 张永宏, 赵艳. 肠道微生物群在肝细胞癌发病机制中的作用[J]. 临床肝胆病杂志, 2019, 35( 7): 1613－ 1615. DOI: 10.3969/j.issn.1001－5256.2019.07.041.
    [46]
    FEDIRKO V, TRAN HQ, GEWIRTZ AT, et al. Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: A nested case－control study[J]. BMC Med, 2017, 15( 1): 72. DOI: 10.1186/s12916－017－0830－8.
    [47]
    XIE GX, WANG XN, HUANG FJ, et al. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis[J]. Int J Cancer, 2016, 139( 8): 1764－ 1775. DOI: 10.1002/ijc.30219.
    [48]
    HUANG R, NI JJ, GAO Y. The association between the intestinal microbiota－lipopolysaccharide－Toll－like receptor 4 axis and hepatocellularcarcinoma[J]. J Clin Hepatol, 2018, 34( 6): 1325－ 1328. DOI: 10.3969/j.issn.1001－5256.2018.06.041.

    黄蓉, 倪加加, 高毅. 肠道菌群－脂多糖－Toll样受体4轴与肝细胞癌的关系[J]. 临床肝胆病杂志, 2018, 34( 6): 1325－ 1328. DOI: 10.3969/j.issn.1001－5256.2018.06.041.
    [49]
    AFFO S, YU LX, SCHWABE RF. The role of cancer－associated fibroblasts and fibrosis in liver cancer[J]. Annu Rev Pathol, 2017, 12: 153－ 186. DOI: 10.1146/annurev－pathol－052016－100322.
    [50]
    YU LX, YAN HX, LIU Q, et al. Endotoxin accumulation prevents carcinogen－induced apoptosis and promotes liver tumorigenesis in rodents[J]. Hepatology, 2010, 52( 4): 1322－ 1333. DOI: 10.1002/hep.23845.
    [51]
    NI JJ, HUANG R, ZHOU HF, et al. Analysis of the relationship between the degree of dysbiosis in gut microbiota and prognosis at different stages of primary hepatocellular carcinoma[J]. Front Microbiol, 2019, 10: 1458. DOI: 10.3389/fmicb.2019.01458.
    [52]
    ZHENG W, ZHAO P, ZHANG YH, et al. Metagenomic analysis on characteristics of intestinal flora of patients with primary liver cancer[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2021, 15( 3): 149－ 157. DOI: 10.3877/cma.j.issn.1674－1358.2021.03.002.

    郑微, 赵鹏, 张永宏, 等. 宏基因组测序技术分析原发性肝癌患者肠道菌群特征[J/CD]. 中华实验和临床感染病杂志(电子版), 2021, 15( 3): 149－ 157. DOI: 10.3877/cma.j.issn.1674－1358.2021.03.002.
    [53]
    BARUCH EN, YOUNGSTER I, BEN－BETZALEL G, et al. Fecal microbiota transplant promotes response in immunotherapy－refractory melanoma patients[J]. Science, 2021, 371( 6529): 602－ 609. DOI: 10.1126/science.abb5920.
    [54]
    ZHOU D, PAN Q, SHEN F, et al. Total fecal microbiota transplantation alleviates high－fat diet－induced steatohepatitis in mice via beneficial regulation of gut microbiota[J]. Sci Rep, 2017, 7( 1): 1529. DOI: 10.1038/s41598－017－01751－y.
    [55]
    WITJES JJ, SMITS LP, PEKMEZ CT, et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis[J]. Hepatol Commun, 2020, 4( 11): 1578－ 1590. DOI: 10.1002/hep4.1601.
    [56]
    BAJAJ JS, SALZMAN NH, ACHARYA C, et al. Fecal microbial transplant capsules are safe in hepatic encephalopathy: A phase 1, randomized, placebo－controlled trial[J]. Hepatology, 2019, 70( 5): 1690－ 1703. DOI: 10.1002/hep.30690.
    [57]
    DEFILIPP Z, BLOOM PP, TORRES SOTO M, et al. Drug－resistant E. coli bacteremia transmitted by fecal microbiota transplant[J]. N Engl J Med, 2019, 381( 21): 2043－ 2050. DOI: 10.1056/NEJMoa1910437.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (389) PDF downloads(39) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return